GLP-1s go beyond the scale; policy snags for prevention

Today's moves show GLP-1s carving out new territory beyond weight loss, while policy struggles to get ahead of health crises.

In today's read: 1. GLP-1s get a nervous system upgrade · 2. Prevention hits policy walls · 3. The climate crisis is a nervous system crisis · 4. Beyond the gut-skin axis: metabolism is the bedrock

1. GLP-1s get a nervous system upgrade

These drugs, designed for metabolic control, are now showing direct impacts on brain function and nervous system regulation. This isn't just about blood sugar; it's about altering inflammation and neural pathways that affect mood and cognition.

Watch for more research on how GLP-1s might treat mental health conditions and neurodegenerative diseases. This expands the market far beyond obesity and diabetes, pulling in big pharma and nervous system specialists.

Evidence from today:

• GLP-1s show psychiatric benefit in schizophrenia, T2D patients — Deutsches Ärzteblatt — A new Lancet Psychiatry study suggests GLP-1 medications may reduce psychiatric hospitalization and ER visits for people with both schizophrenia and type 2 diabetes. The research followed over 60,000 adults in Australia, finding a clear reduction in acute psychiatric care needs over 180 days. It suggests these drugs might offer more than just metabolic control, impacting nervous system regulation directly.
• Semaglutide's heart benefits go beyond weight loss — Deutsches Ärzteblatt — New analysis of the SELECT trial published in European Heart Journal 2026 confirms that semaglutide reduces cardiovascular risk. This effect isn't just from weight loss or improved metabolic markers, suggesting a direct mechanism for heart protection. It means people using GLP-1s might get more than just scale victories.
• Oral GLP-1s show heart benefits beyond safety — The Lancet — New data from The Lancet highlights how GLP-1 receptor agonists, including the oral form orforglipron, are moving past just proving cardiovascular safety. The latest trials show these drugs actually reduce major adverse cardiovascular events and offer kidney protection, not just for injectables but for oral versions too.

2. Prevention hits policy walls

Despite clear health benefits, government bodies are slow to adopt proactive strategies, whether due to bureaucracy, data concerns, or misaligned priorities. This leaves gaps in public health and shifts the burden to individual citizens.

This pattern means private wellness initiatives will keep filling the void. Companies focused on individual diagnostics and proactive health management will thrive where public policy fails to scale up preventative measures.

Evidence from today:

• German government rejects dedicated sepsis registry — Deutsches Ärzteblatt — Germany's federal government won't create its own national sepsis registry, citing high bureaucracy and patient data complexities. This decision, in response to a Green party inquiry, means the country will continue to rely on existing data sources, likely missing crucial insights into a leading cause of death.
• Simple exercise beats complex fall prevention for older adults — Deutsches Ärzteblatt — A Cochrane Review published in Deutsches Ärzteblatt finds that personalized fall prevention programs for older adults are no more effective than basic exercise and training. The review suggests that simpler, less resource-intensive interventions can yield similar results in reducing falls.
• Osteoporosis Prevention Needs to Start During Perimenopause, Say Spanish Experts — El Médico Interactivo — Spanish medical societies FHOEMO and SEIOMM are pushing for osteoporosis prevention to begin earlier, specifically during perimenopause. They highlight the need for personalized approaches to prevent the first fracture. The goal is to shift intervention to a crucial hormonal window, before significant bone density loss sets in.

3. The climate crisis is a nervous system crisis

Environmental disasters and systemic inequalities are not just external events; they create chronic stress, disrupt nervous system regulation, and lead to measurable mental and physical health declines. It's a direct biological hit from the environment.

This isn't about 'eco-anxiety' as a separate issue. It's about a fundamental breakdown of human-environment equilibrium. Solutions must address both external causes and the internal biological load on the nervous system. Watch for investment in community resilience and stress mitigation tools.

Evidence from today:

• Ecosystem changes drive animal-to-human disease spread — Deutsches Ärzteblatt — New research from Rory Gibb at University College London, published in Nature, links human-caused ecosystem fragmentation and altered rainfall patterns to an increased risk of diseases jumping from animals, mosquitoes, and ticks to humans. This meta-analysis of global data connects environmental shifts directly to human health, forecasting a rise in infectious outbreaks. It's a stark reminder of how environmental changes hit our biology.
• Flood trauma in Lismore links climate to nervous system health — Croakey Health Media — An award-winning documentary, 'The Flood is a Terrible Thing,' explores the long-term mental and physical health impacts of catastrophic flooding in Lismore, Australia, on individuals and communities. It highlights how climate-related disasters affect nervous system regulation and stress response, even years later. The film argues for better community-led recovery approaches.
• Experts demand end to hospital racism, citing war's toll on children's health — Croakey Health Media — An international group of child health experts is calling for an end to racism in hospitals, emphasizing its impact on children traumatized by war. This follows the cancellation of a medical education event at Perth Children's Hospital focused on the psychological and physical toll of conflict.

4. Beyond the gut-skin axis: metabolism is the bedrock

We've talked about the gut-skin connection for a while, but now the evidence points to underlying metabolic health as the real driver. Inflammation, driven by metabolism, impacts everything from skin conditions to hormone regulation and treatment efficacy.

Targeting metabolic pathways, rather than just surface symptoms, is the next frontier. Companies that can accurately assess and intervene in metabolic health for a range of conditions will win. Look for integrated solutions for weight, hormones, and inflammatory diseases.

Evidence from today:

• Psoriasis and obesity link examined in new webinar series — El Médico Interactivo — A new webinar moderated by Prof. Puig and featuring Prof. Pinter and Prof. Costanzo is digging into the global burden of obesity in psoriasis patients. They're looking at how a patient's BMI impacts treatment effectiveness and persistence for the inflammatory skin condition. It's an overdue look at how weight directly affects chronic disease outcomes.
• Psoriasis and obesity linked to poorer treatment outcomes — El Médico Interactivo — A Spanish medical webinar highlighted how obesity impacts psoriasis treatment effectiveness and persistence. Professors Puig, Pinter, and Costanzo explored real-world evidence showing higher BMI leads to worse outcomes for psoriasis patients. It emphasizes considering metabolic health for inflammatory conditions.
• Digbi Health adds menopause, HRT to gut microbiome platform — Longevity.Technology — Digbi Health, a personalized gut health platform, is now offering services specifically for menopause, integrating hormone replacement therapy (HRT) data. The company leverages its extensive gut microbiome data to provide insights and support for menopausal symptoms. This move targets the significant intersection of gut health and hormonal changes during midlife.

Also moved today

• ADHD links to higher dementia risk after 50 — Healio - Psychiatry & Mental Health — ADHD after 50 increases dementia risk four-fold, showing a higher nervous system load.
• New biotech Estuary launches for gene therapy research on ADPKD — Inside Precision Medicine — Estuary Biotherapeutics launched, focusing on gene therapies for ADPKD, a serious kidney disease.
• Prenuvo opens 200,000 whole-body MRI scans for research — Longevity Technology — Prenuvo opened 200,000 whole-body MRI scans for research, aiming to advance early detection of abnormalities.
• New targeted therapy shrinks recurring brain tumors in trial — Nature Medicine RSS — A new targeted therapy shrank recurring brain tumors in 29% of patients in an early trial, offering hope for difficult cancers.
• EMA Recommends Approval for Oral GLP-1 Orforglipron — Deutsches Ärzteblatt — The EMA recommended approval for Orforglipron, an oral GLP-1, expanding options for obesity and Type-2 Diabetes in Europe.
• Optogenetics restores some vision in retinitis pigmentosa patients — Nature Medicine RSS — Optogenetics partially restored vision in five patients with retinitis pigmentosa, a significant biotech step for nervous system repair.
• German Medical Association Debunks Contraception Myths, Advises on Hormones — Deutsches Ärzteblatt — Germany's Medical Association released new guidelines to combat contraception misinformation, pushing evidence-based hormone advice.
• Private equity firm buys Greek yogurt bar brand Clio Snacks — New Hope Network (Natural Products Expo) — Private equity bought Clio Snacks, signaling continued investment in gut-friendly, protein-rich packaged foods.
• Medical Pros Now Asking AI for Health Info — Deutsches Ärzteblatt — Medical professionals are increasingly using AI for health information, with over 270 million queries to OpenEvidence in 2.5 years.

New this week in wellness goods

• New biotech Estuary launches for gene therapy research on ADPKD — north_america — Estuary Biotherapeutics just launched, focusing its efforts on developing gene therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The team is stacked with genetic medicine, kidney biology, and drug development experts, aiming to bring these therapies to human patients.

Signal map

Europe: 23 · UK & Ireland: 15 · North America: 12 · Global: 9 · Oceania: 5 · Nordics: 1

What I'd watch next

Keep an eye on the broader uptake of digital-first GLP-1 delivery models, and how regulatory bodies in different countries react to increasing evidence of GLP-1s' non-metabolic benefits. I’m watching Germany's biosimilar savings to see how cost-cutting in medicine might free up resources for preventative health.

Where this fits at Kokorology

Understanding these body-market patterns is how you stay ahead. I put all my research into the Daily Hacks, so you don't have to.